Overview
Three of five vital signs, core body temperature, heart rate and blood pressure reflect disruption to highly regulated systems. Critical care includes a pharmacopeia of vasopressors that have become a therapeutic cornerstone for the management of several important cardiovascular syndromes. Similar advances have not yet been made for management of core body temperature.
Overview
Three of five vital signs, core body temperature, heart rate and blood pressure reflect disruption to highly regulated systems. Critical care includes a pharmacopeia of vasopressors that have become a therapeutic cornerstone for the management of several important cardiovascular syndromes. Similar advances have not yet been made for management of core body temperature.
Team

Kelly L. Drew, phd

Chief Executive Officer

Publications

Prof. Drew serves in the Department of Chemistry and Biochemistry at the University of Alaska Fairbanks with over 70 peer-reviewed publications and 30 years experience in biomedical research focused on hibernation and brain injury.

Benjamin Mattes, Phd

Director of Operations

Publications

Dr. Mattes is an established entrepreneur of small research and development companies, and former founder, CEO and President, Santa Fe Science and Technology.

Bernard W. Laughlin, DO

Chief Scientific Officer

Publications

Clinician/Scientist leading preclinical studies.

Numerous student and graduate researchers are also participating on this development.

Kelly Seekatz

Chief Fiscal Officer
30 years experience in bookkeeping and grants management
Invest

Why Invest?

Customer discovery, a technology niche analysis, and FDA guidance identified opportunity for market entry through neurocritical care with orphan drug status for cardiac arrest, subarachnoid hemorrhage or spinal cord injury and a large, $3B annual market based on a SOM of 20 percent for post-operative shivering.

Target Market

Total available market of over 1,300,000 patients includes stroke and cardiac arrest patients with control of neurogenic fever after subarachnoid hemorrhage as a primary indication. Other types of stroke and cardiac arrest are secondary indications. Post-operative shivering is the largest market with 310 million major surgeries performed globally per year.

Business Model

BeCool Pharmaceutics is a small molecule drug development company, focused on creating therapeutics to modulate metabolism and body temperature by mimicking mechanisms used in hibernation.

BCP 190 and 191 follow a traditional drug development model.

Achievements

  • Preclinical validation
  • At IND enabling stage
  • Continuing preclinical large and small animal efficacy studies
  • ITHS early product development grant awarded
  • M.J. Murdock Charitable Trust, Commercialization grant awarded
Contact

Kelly Drew
907.388.5311
kdrew@becoolpharma.com